Equities

Cytodyn Inc

Cytodyn Inc

Actions
  • Price (USD)0.1628
  • Today's Change-0.005 / -3.10%
  • Shares traded1.19m
  • 1 Year change-13.17%
  • Beta0.1137
Data delayed at least 15 minutes, as of Sep 18 2024 20:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.

  • Revenue in USD (TTM)0.00
  • Net income in USD-51.32m
  • Incorporated2018
  • Employees9.00
  • Location
    Cytodyn Inc1111 Main St Ste 660VANCOUVER 98660-2970United StatesUSA
  • Phone+1 (360) 980-8524
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cytodyn.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DiaMedica Therapeutics Inc0.00-19.90m185.95m18.00--3.48-----0.5238-0.52380.001.250.00----0.00-33.49-45.38-34.98-48.24------------0.0006-------41.72---13.65--
Caribou Biosciences Inc33.11m-123.44m189.76m158.00--0.6112--5.73-1.39-1.390.37633.440.0917--15.61209,576.00-34.17---37.56-------372.78-----1,231.110.00--148.91---2.66------
Gossamer Bio Inc95.84m-80.85m203.31m135.00--2.49--2.12-0.3996-0.39960.4340.36040.3453----709,940.80-29.13-57.43-34.41-64.38-----84.36-----7.070.7073------21.61------
CytoDyn Inc0.00-51.32m204.10m9.00---------0.0527-0.05270.00-0.11030.00----0.00-444.45-259.15-----------232,918.20---2.76--------35.70------
Cabaletta Bio Inc0.00-89.98m204.68m136.00--1.01-----1.92-1.920.004.130.00----0.00-44.76-33.76-47.90-35.68------------0.00-------27.75------
Vaxart Inc13.93m-75.66m210.27m109.00--2.63--15.10-0.4707-0.47070.08610.35180.1178--5.80127,779.80-64.01-49.60-73.18-54.86-----543.21-1,398.00---226.730.0507--6,796.2612.1523.47--21.49--
MacroGenics Inc41.02m-136.37m211.06m339.00--3.65--5.15-2.19-2.190.65830.92180.16196.626.51120,997.00-53.82-37.76-67.56-45.5379.37---332.47-133.962.69-172.620.00---61.33-0.460692.44---41.13--
Pyxis Oncology Inc16.15m-59.20m212.78m51.00--1.25--13.18-1.26-1.260.32692.880.0842----322,920.00-30.87---33.12--97.06---366.67------0.0008------38.87------
Fulcrum Therapeutics Inc81.63m-20.23m217.78m76.00--0.7935--2.67-0.3507-0.35071.314.400.2746--29.131,074,079.00-6.81-50.55-7.14-55.91-----24.79-1,189.10----0.00---55.77--11.41---43.70--
Codexis Inc60.89m-76.36m224.13m174.00--3.65--3.68-1.09-1.090.87230.86650.35956.273.58349,942.50-45.08-17.13-56.05-20.2377.9577.29-125.41-37.042.92--0.3158---49.392.97-126.96--9.80--
XBiotech Inc0.00-35.01m225.12m94.00--1.14-----1.15-1.150.006.460.00----0.00-15.5331.88-16.3233.27------877.30----0.04840.00-100.00--25.36--24.30--
Candel Therapeutics Inc0.00-49.99m225.40m42.00---------1.70-1.700.00-0.3210.00----0.00-117.35---158.61-------------32.702.36---100.00---101.87------
Data as of Sep 18 2024. Currency figures normalised to Cytodyn Inc's reporting currency: US Dollar USD

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Diversified Trust Co.as of 30 Jun 202445.79k0.00%
Virtue Capital Management LLCas of 30 Jun 202445.00k0.00%
Moloney Securities Asset Management LLCas of 30 Jun 202428.03k0.00%
Williams Jones Wealth Management LLCas of 30 Jun 202425.00k0.00%
S.A. Mason LLCas of 30 Jun 202419.00k0.00%
Horizon Financial Services LLCas of 30 Jun 202418.20k0.00%
FineMark National Bank & Trust (Invt Mgmt)as of 30 Jun 202415.00k0.00%
Willis Investment Counsel, Inc.as of 30 Jun 202413.04k0.00%
Ancora Family Wealth Advisors LLCas of 30 Jun 20249.49k0.00%
Able Wealth Management LLCas of 31 Dec 20235.91k0.00%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.